Femasys (NASDAQ:FEMY) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Femasys (NASDAQ:FEMY) in a research note released on Wednesday morning,Benzinga reports. They currently have a $12.00 price target on the stock.

Separately, Chardan Capital cut their target price on shares of Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Femasys Stock Down 1.9 %

Shares of FEMY stock opened at $1.04 on Wednesday. The stock’s 50 day simple moving average is $1.14 and its 200 day simple moving average is $1.13. Femasys has a twelve month low of $0.73 and a twelve month high of $2.40. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. The company has a market capitalization of $23.82 million, a price-to-earnings ratio of -1.28 and a beta of -2.83.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The firm had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. As a group, research analysts predict that Femasys will post -0.84 EPS for the current year.

Hedge Funds Weigh In On Femasys

Institutional investors and hedge funds have recently bought and sold shares of the stock. CM Management LLC boosted its holdings in Femasys by 6.3% in the 2nd quarter. CM Management LLC now owns 425,000 shares of the company’s stock valued at $484,000 after purchasing an additional 25,000 shares during the period. Geode Capital Management LLC lifted its stake in shares of Femasys by 9.2% in the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after buying an additional 17,473 shares during the period. XTX Topco Ltd lifted its stake in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after buying an additional 18,004 shares during the period. Finally, Aljian Capital Management LLC acquired a new stake in Femasys during the third quarter worth about $27,000. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.